// App-Quantinova.ai

590 : Efficacy of MDX-124, a novel anti-annexin-A1 antibody, in preclinical models of pancreatic cancer.

Researchers

Presenter

  • Fiona C. Dempsey

Principal Investigators

  • Hussein Al-Ali

  • Scott J. Crichton

  • Charlene Fabian

  • Emily Roberts

  • Chris Pepper

  • Michael C. Schmid

  • Christopher N. Parris

Medical Centers

  • Medannex Limited, Edinburgh, United Kingdom

  • INIVATA, Cambridge, United Kingdom

  • Brighton and Sussex Medical School, Brighton, United Kingdom

  • University of Liverpool, Liverpool, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Metastatic pancreatic adenocarcinoma

  • Pancreatic and cerebellar agenesis

Biomarkers

  • Melanoma-inhibitory activity

Drug/Treatment

  • MDX-001

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved